Boehringer Ingelheim announced the submission of Marketing Authorization Applications (MAAs) in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol Respimat as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD). The applications are based on data from the large Phase 3 TOviTO clinical trial program. Further submissions in additional countries will be announced in due course.Tiotropium + olodaterol FDC is an investigational treatment that contains the world’s most prescribed COPD maintenance therapy, tiotropium (Spiriva), combined with olodaterol (Striverdi), a new once-daily and fast-acting LABA, delivered by the Respimat Soft Mist Inhaler.
“The submission of tiotropium + olodaterol for marketing authorisation is a milestone for Boehringer Ingelheim and builds on nearly 100 years of experience in this therapy area of respiratory medicine,” said Dr. Brian Wong, head of Medical and Scientific Affairs, Boehringer Ingelheim UK. “Once approved, tiotropium + olodaterol will realize our commitment to constant innovation by offering patients an additional treatment option for a disease that affects over a million people in the UK.”
Date: July 2, 2014
Source: Boehringer Ingelheim
